Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

AstraZeneca Earns Buy Rating with 28% Upside Potential on Regulatory Wins and Encouraging Pipeline

AstraZeneca PLC (LSE:AZN.L) has received a reaffirmed BUY rating from analysts, with a current average target price of GBp 13,272.90—representing a 28.09% upside from its latest traded price. The recommendation is supported by its clinical pipeline, and a series of regulatory approvals that boosts …

Team Kalkine | 10 July 2025

BSF Enterprise (LSE:BSFA) Signs Exclusive Global IP Agreement for LiQD Cornea Technology

BSF Enterprise PLC (LSE:BSFA), a UK-based biotechnology company focused on tissue-engineered materials, announced on 10 July 2025 that its wholly owned subsidiary, Kerato Limited, has entered into an exclusive worldwide option agreement with Université de Montréal. The agreement grants Kerato the global rights to …

Team Kalkine | 10 July 2025

Aptamer Group Raises AUD 3.8 Million via Share Placing to Support Growth and Licensing Pipeline

Aptamer Group plc (LSE:APTA)has raisedAUD 3.8 millionbefore expenses through a placing of ordinary shares to new and existing shareholders. The capital raise includes a firm placing and a conditional placing of a combined666,666,666 new Ordinary Sharesat an issue price of 0.3 pence per share, …

Team Kalkine | 04 July 2025

Avacta (LSE:AVCT) Reports Clinical Progress and Board Changes Ahead of AGM

Avacta Therapeutics plc (LSE:AVCT),a UK-based clinical-stage life sciences company, provided a business update ahead of its 2025 Annual General Meeting, outlining recent progress across its oncology pipeline and key corporate developments.

Team Kalkine | 02 July 2025

Spire Healthcare Earns Double BUY Ratings with Up to 31% Upside Potential

Spire Healthcare Group plc (LSE:SPI), one of the UK's largest independent healthcare providers, has been rated aBUYby both Berenberg and Panmure Liberum, with analysts forecastingup to 31.34% upsidefrom its current share price ofGBp 217.0. Target prices ofGBp 280 and GBp 285reflect market confidence in …

Team Kalkine | 26 June 2025

Avacta Therapeutics Reports FY24 Results, Sharpens Focus on Oncology Drug Development

Avacta Therapeutics plc (LSE:AVCT), a UK-based life sciences company specialising in oncology therapeutics, has released its unaudited preliminary financial and operational results for the full year ended December 31, 2024 (FY24). The company marked a pivotal year in its transformation into a pure-play oncology …

Team Kalkine | 06 June 2025

Dr. Martens Charts Path to Profit Recovery in FY26 Following Strategic Reset

Dr. Martens plc (LSE:DOCS)has reported its preliminary results for the 52 weeks ending 30 March 2025, with management declaring the year as one of significant strategic progress despite a drop in headline financials. The company now expects to return to profit growth in FY26 …

Team Kalkine | 05 June 2025

hVIVO Faces Contract Cancellation and Trial Postponement Amid Sector Uncertainty

hVIVO plc (LSE:HVO)is a UK-based contract research organisation specialising in human challenge clinical trials. The company also offers laboratory and early-phase clinical trial services through its subsidiaries, including CRS and Venn.

Team Kalkine | 30 May 2025

ANGLE Reports FY2024 Results with Narrowed Loss and Continued Focus on Pharma Collaborations

ANGLE plc (LSE:AGL),a UK-based liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has released its audited preliminary financial results for the year ended 31 December 2024. The company reported a reduction in operating loss alongside a revenue increase, following operational restructuring and …

Team Kalkine | 28 May 2025

Poolbeg Pharma Gains FDA Orphan Drug Status for Groundbreaking CRS Prevention Treatment

Poolbeg Pharma PLC(LSE:POLB) has achieved a major regulatory milestone in the United States, announcing that theFood and Drug Administration (FDA)has grantedOrphan Drug Designation (ODD)for its lead candidatePOLB 001, an oral therapy developed toprevent cytokine release syndrome (CRS).

Team Kalkine | 27 May 2025
Support

Hi! How can we help you today?

Loading…